More on PHRRF

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:PHRRF)
Delayed: 0.04 --0 (-0%)
Prev. Close $0.04  
Open$0.04 
52 Wk High$ 
52 Wk Low$ 
Day High$0.04 
Day Low$0.04 
P/E N/A  
EPS$ 
Volume49 

Friends, Peers and Foes (?): PHRM, LMLLF PHRX (more...)

Oct 7, 2026 08:01 AM PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Oct 5, 2026 08:02 AM PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Oct 1, 2026 08:02 AM PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
Aug 18, 2026 08:02 AM PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Aug 11, 2026 08:02 AM PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Jul 29, 2026 08:02 AM PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Jul 27, 2026 08:02 AM PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Jul 21, 2026 08:02 AM PharmaTher partners with KetaMist inventor to seek FDA approval
Jul 21, 2026 08:02 AM PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Jul 15, 2026 08:02 AM PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
View All Articles

Entities mentioned with PHRRF

View All Entities